CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, ...

Moderna, Inc. remains under pressure in 2025, despite recent next-gen COVID vaccine approval & cancer vaccine trial. Learn ...

rVE was consistent across vaccine-included strains ... Presenter: Brett Leav, MD Time: Monday, October 20, 3:15-4:30pm ET Location: B207-B208 Moderna will also present the following: Moderna is a ...

Discover whether Moderna or BioNTech offers better long-term investment potential as both pivot from COVID-19 to innovative ...

Moderna's decision not to diversify outside of COVID has hurt its business substantially. The company is still generating ...

Private contractors hired by Moderna Inc to recruit volunteers for its coronavirus vaccine trial failed to enroll enough Black, Latino and Native American participants to determine how well the ...

Over the past five years, 800 million people worldwide have been infected with COVID-19. The death toll has reached 7 million. Even now, deaths continue to occur. COVID-19 is now trending toward ...

Moderna Inc said on Monday it has applied for U.S. emergency authorization for its COVID-19 vaccine after full results from a late-stage study showed it was 94.1% effective with no serious safety ...

Covid-19 infections continue to climb nationwide. And while updated vaccines are available, there is growing confusion over ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...

After weeks of confusion, approval by CDC and its acting director mean most Nebraskans can get COVID-19 vaccines after consulting with a health care provider, including pharmacists.

A school district balked at the request for the Supreme Court to micromanage California’s schools’ health policy on the ...